Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industryBig pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.{}

Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.https://www.cnbc.com/2026/01/20/drug-pricing-patent-losses-deals-novo-nordisk-pfizer.html